英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Rendezvousing查看　Rendezvousing　在百度字典中的解释百度英翻中〔查看〕
Rendezvousing查看　Rendezvousing　在Google字典中的解释Google英翻中〔查看〕
Rendezvousing查看　Rendezvousing　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
    Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for
  • Lost in translation: Revisiting the use of tyrosine kinase . . .
    Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment
  • Zanzalintinib Atezolizumab Improves CRC Survival, Expands TKI . . .
    New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options
  • Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
    Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine ki …
  • Fruquintinib: a novel antivascular endothelial growth factor . . .
    Several small-molecule anti-VEGFR tyrosine kinase inhibitors (TKIs), such as regorafenib, famitinib, axitinib and apatinib, have been shown to be effective in treating metastatic colorectal cancer (mCRC) Fruquintinib (ELUNATE ®) is a novel oral anti-VEGFR TKI, originated and developed by Hutchison MediPharma
  • Targeted Therapy in Metastatic Colorectal Cancer: Current . . .
    Treatment options for patients with metastatic colorectal cancer continue to advance as the therapeutic implications of the molecular subtypes of this disease are becoming better understood DNA sequencing and mismatch repair assessment are now
  • A multi-center effectiveness comparison study of fruquintinib . . .
    A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
  • A multi-center effectiveness comparison study of fruquintinib . . .
    With the approach of establishing the external control arm from RWD, this study has demonstrated that treatment with fruquintinib significantly prolonged PFS as compared to other TKIs in patients as third-line mCRC treatment
  • Emerging tyrosine kinase inhibitors for the treatment of . . .
    Abstract Introduction: Colorectal cancer (CRC) is a leading cause of cancer death worldwide Over the last decade, the addition of antibodies that block the epidermal growth factor receptor (EGFR) or angiogenesis to the classic chemotherapy backbone has improved overall survival in metastatic colorectal cancer (mCRC) However, the role of the other major targeted therapy, the tyrosine kinase
  • RETRACTED ARTICLE: Rechallenge therapy versus tyrosine kinase . . .
    Colorectal cancer (CRC) is the third most common cause of cancer and the second most common cause of cancer-related death worldwide At least 50% of patients will experience metastasis, with the





中文字典-英文字典  2005-2009